Azelastine: Nursing Drug Guide, Somnolence & NCLEX Review
Topical H1 blocker for allergic and vasomotor rhinitis—but systemic absorption can cause somnolence, and alcohol or sedating co-meds stack CNS depression. Pair every dose with prime status, head-down spray technique, eye-splash prevention, and alertness screening before discharge or driving.
Labeling for azelastine HCl nasal spray, 0.1% reports somnolence and warns patients not to drive or operate machinery. Alcohol and other CNS depressants can further reduce alertness—avoid concurrent use. Even intranasal dosing delivers measurable systemic drug (~40% bioavailability). Bitter taste and poor technique are common; spraying into the eyes causes irritation and is preventable with head-down positioning.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm bottle strength, prime status, and whether the patient took alcohol or sedating antihistamines. Teach head-down technique to limit bitter taste and eye exposure. If the patient is sleepy, do not clear them to drive—contact pharmacy/prescriber about CNS stacking.
Brand names and formulations
Azelastine hydrochloride (HCl) is available as an intranasal metered spray and as ophthalmic drops. This guide focuses on nasal spray 0.1% (137 mcg per spray), the strength reviewed in current U.S. prescribing information for seasonal allergic rhinitis and vasomotor rhinitis.
- Nasal spray 0.1%: Astelin; generic azelastine HCl nasal spray
- Nasal spray 0.15%: Astepro and generics (different age thresholds and once-daily option—verify the specific product label)
- Combination: Azelastine/fluticasone nasal spray (separate product—not interchangeable with azelastine alone)
- Ophthalmic 0.05%: Allergic conjunctivitis drops—different indication, route, and dosing; not covered in depth here
Indications
Per azelastine HCl nasal spray, 0.1% labeling:
- Seasonal allergic rhinitis symptoms in adults and pediatric patients 5 years and older
- Vasomotor (nonallergic) rhinitis symptoms in adults and adolescents 12 years and older
Nurses often see azelastine ordered for nasal congestion, sneezing, rhinorrhea, and postnasal drip when oral antihistamines are insufficient or sedating. It does not replace epinephrine or systemic therapy for anaphylaxis.
How it works
Azelastine is a histamine H1-receptor antagonist (antihistamine) administered intranasally. It blocks histamine-mediated nasal symptoms and also has anti-inflammatory activity in the nasal mucosa per labeling. Systemic absorption after intranasal dosing is approximately 40%, which is why somnolence and CNS effects can occur even though the drug is a topical spray.
Dosing
Intranasal route only. Confirm product strength (0.1% vs 0.15%) before teaching or administering.
Azelastine HCl nasal spray 0.1% (137 mcg/spray)
| Indication / population | Dose |
|---|---|
| Seasonal allergic rhinitis — ages 5–11 | 1 spray per nostril twice daily |
| Seasonal allergic rhinitis — ages 12+ | 1 or 2 sprays per nostril twice daily |
| Vasomotor rhinitis — ages 12+ | 2 sprays per nostril twice daily |
On a small screen, swipe or scroll sideways to see the full table.
Priming and technique
- Initial prime: 4 sprays or until a fine mist appears
- Re-prime: 2 sprays if unused for 3 or more days
- Keep head tilted downward when spraying; alternate nostrils; breathe gently to avoid drawing medication into the throat
- Avoid spraying into the eyes—ocular exposure can cause irritation
A separate 0.15% nasal spray formulation exists with different pediatric age limits and an optional once-daily regimen—always match technique and dose to the bottle the patient is holding.
Pharmacokinetics
- Onset: Not specified in the reviewed prescribing information for intranasal 0.1% spray
- Peak plasma: 2–3 hours after intranasal administration
- Half-life: Approximately 22 hours (based on oral/intravenous data in labeling)
- Metabolism: Oxidized to desmethylazelastine (active H1 antagonist)
- Renal impairment: Oral data show higher Cmax and AUC when creatinine clearance <50 mL/min—use caution; intranasal-specific adjustments not specified in the reviewed prescribing information
Safety check — Before you give
Answer these before the first dose or when resuming home supply:
- Correct patient, drug, strength (0.1% vs 0.15%), sprays per nostril, and schedule (BID)
- Spray bottle primed (initial 4 sprays; 2 sprays if unused ≥3 days)
- Recent alcohol, opioid, benzodiazepine, or other sedating medication—labeling warns against concurrent CNS depressants
- Occupation requiring alertness (driving, machinery)—somnolence reported in trials
- Planned activities after dose—avoid hazardous tasks if drowsy
- Eye symptoms after spray—teach to avoid ocular exposure; rinse eyes if sprayed
- Concurrent intranasal products—clarify order sequence with pharmacy if multiple nasal sprays ordered
- Pregnancy or breastfeeding—shared decision per labeling; monitor breastfed infant for feeding changes (bitter taste)
Contraindications
None listed for azelastine HCl nasal spray, 0.1% in the reviewed U.S. prescribing information. Use clinical judgment for known hypersensitivity to azelastine or formulation components (benzalkonium chloride preservative in 0.1% product).
Drug interactions
| Agent | Effect | Nursing action |
|---|---|---|
| Alcohol | Further decreased alertness and impaired CNS performance | Counsel to avoid alcohol while using spray; assess sedation before discharge or driving |
| CNS depressants (e.g., diphenhydramine, opioids, sedative-hypnotics) | Additive sedation and psychomotor impairment per labeling | Screen MAR and home meds; coordinate with pharmacist before stacking sedating antihistamines |
| Cimetidine | Oral azelastine AUC increased ~65% with cimetidine in labeling interaction studies | Not specified in the reviewed prescribing information for intranasal spray—flag new acid-reducing therapy for pharmacist review |
| Other intranasal agents | No formal interaction data in reviewed labeling | Separate administration timing per facility protocol if steroid or saline sprays also ordered |
On a small screen, swipe or scroll sideways to see the full table.
Administration
- Blow nose gently; keep head forward (not hyperextended)
- Prime pump before first use and after ≥3 days without use
- Insert tip into nostril without deep insertion; aim away from nasal septum
- Alternate nostrils when bilateral dosing; sniff gently only
- Wipe tip; replace cap to prevent clogging
- Document sprays per nostril, time, and patient tolerance (bitter taste, sneezing)
Spraying with head back, sniffing forcefully, or aiming at the septum increases bitter taste, sneezing, and eye exposure. Unprimed pumps deliver subtherapeutic doses while the nurse believes the dose was given.
Expected therapeutic response
- Reduced sneezing, rhinorrhea, nasal itching, and congestion over days of regular BID use
- Patient may notice bitter taste after spray—expected adverse effect, not an allergy by itself
- If no improvement after appropriate trial, prescriber may adjust dose (1 vs 2 sprays per nostril in seasonal allergic rhinitis ages 12+) or change therapy
Red flags — Stop and act
- Anaphylaxis signs (urticaria, angioedema, bronchospasm, hypotension)—postmarketing reports include anaphylaxis; stop drug and treat per emergency pathway
- Severe somnolence, confusion, or inability to arouse after dose—hold and evaluate CNS depressant stacking
- Significant eye pain, vision changes, or persistent eye irritation after spray—ophthalmology/prescriber follow-up
- Heavy epistaxis or nasal sores that worsen—notify prescriber
- Application-site irritation severe enough to stop therapy
Adverse effects
Most common adverse reactions (≥2% incidence) per azelastine HCl nasal spray, 0.1% labeling:
| Adverse effect | Nursing notes |
|---|---|
| Bitter taste | Very common (~20% in 2-spray BID trials); teach expectation; rinse mouth if bothersome |
| Headache | Common; assess hydration and concurrent causes |
| Somnolence | ~12% at 2 sprays/nostril BID vs ~5% placebo; caution driving/machinery |
| Nasal burning, paroxysmal sneezing, epistaxis | Local irritation; review technique and priming |
| Dizziness, fatigue, dry mouth, nausea | Supportive care; assess sedation risk |
| Weight increase | Reported at ≥2% in seasonal allergic rhinitis trials—monitor per prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Postmarketing reports include anaphylaxis, palpitations, dyspnea, rash, loss of smell/taste, and vision abnormalities—report per facility policy.
Overdose, toxicity, and antidote
No overdoses with azelastine HCl nasal spray, 0.1% are reported in labeling. Acute overdose by adults is unlikely to cause clinically significant reactions beyond increased somnolence because one bottle contains 30 mg azelastine HCl. Oral ingestion of antihistamines can cause serious effects in young children—keep spray out of reach.
Antidote
No known antidote for azelastine HCl nasal spray, 0.1% per prescribing information. Provide general supportive measures if overdose occurs.
Contact local poison control or medical toxicology for intentional ingestion or severe sedation per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Azelastine vs azithromycin—different drug classes; verify MAR spelling
- Azelastine monotherapy vs azelastine/fluticasone combination—not interchangeable; combination adds corticosteroid
- 0.1% vs 0.15% nasal spray—different sprays per nostril and age limits
- Nasal spray vs ophthalmic drops—route error causes harm; store separately
- Astelin vs Astepro—brand strength differs; teach-back device patient brought from home
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Bitter taste | Warn before first dose—improves adherence; not a reason to skip without prescriber input |
| Sedation screening | Ask about night shift, driving, or alcohol; somnolence can occur even with intranasal route |
| Pump priming | Document that bottle was primed; unprimed pumps are a common “ineffective drug” call |
| Eye splash | Rinse eyes with water if sprayed; monitor for irritation |
| Commonly missed | Patient continues oral sedating antihistamine while starting azelastine—double sedation risk |
| Ask pharmacy when | Multiple nasal inhalers, unclear strength, or transition from oral loratadine to intranasal therapy |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pediatrics (5–11 seasonal allergic rhinitis) | Fixed dose 1 spray/nostril BID—do not use adult two-spray regimen |
| Adolescents and adults on sedatives | Avoid alcohol and CNS depressants; monitor for additive somnolence |
| Older adults | Labeling notes insufficient geriatric trial numbers—start cautiously; fall risk if sedated |
| Pregnancy | Limited human data; animal oral studies showed harm at very high multiples of intranasal dose—use only if benefit justifies risk per prescriber |
| Lactation | No human milk data; monitor breastfed infant for milk rejection (bitter taste) per labeling |
| Renal impairment | Oral PK shows higher exposure when creatinine clearance <50 mL/min—caution; intranasal adjustment not specified in reviewed labeling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Level of sedation, dizziness, and ability to perform alertness-dependent tasks
- Nasal symptom relief (congestion, sneezing, rhinorrhea) and local irritation
- Blood pressure or heart rate if palpitations reported (postmarketing)
- Eye symptoms after administration
- Signs of systemic allergic reaction after first doses
Document
- Product strength, sprays per nostril, time, prime status, and patient teaching on bitter taste and sedation
- CNS depressant and alcohol counseling provided
- Prescriber notification if somnolence limits safe discharge or work duties
Patient teaching
- Expect a bitter taste—it is common and does not mean you are allergic
- Prime the bottle before first use and after 3+ days without use; keep head tipped down while spraying
- Do not drive or operate machinery if you feel sleepy; avoid alcohol and sedating allergy pills unless prescriber approves
- Aim spray into the nose, not the eyes—rinse eyes with water if accidental exposure
- Seek urgent care for throat swelling, trouble breathing, or widespread rash
- Bring the exact bottle to appointments so the team verifies strength and technique
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to azelastine or serious allergic reaction after prior dose
- Severe somnolence, confusion, or inability to stay awake—especially with concurrent CNS depressants or alcohol
- Wrong product (ophthalmic drops, combination spray, or 0.15% vs 0.1%) relative to the order
- Unprimed device and nurse cannot verify dose delivered after appropriate priming attempts
- Patient must drive or perform hazardous work immediately and reports prior sedation on azelastine—clarify timing or alternative therapy
- Pregnancy or breastfeeding concerns not yet discussed with prescriber when therapy is newly started
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Azelastine is a topical antihistamine, but systemic absorption makes sedation a real nursing problem—especially when sedating oral antihistamines or opioids are still on the MAR.
1. Check-before-you-give protocol
- Right product, strength, sprays per nostril, route (intranasal only), and prime status
- Screen alcohol and CNS depressants on MAR and home med list via medication reconciliation
- Assess baseline alertness and fall risk before evening dose
- Observe return demonstration—head position and gentle sniffing
2. High-alert and safety badge
Not a traditional high-alert medication on all lists—treat sedation + driving risk as the primary safety story3. Clinical workflow: hold and question rules
- If somnolence appears after the first inpatient dose, hold further doses until prescriber reviews sedating co-medications
- If symptoms suggest anaphylaxis, stop azelastine and manage per emergency protocol—not as a local spray reaction alone
- Pair inadequate rhinitis control with prescriber review before patients self-escalate to extra sprays
4. Critical teach-back questions
- “What side effect should you expect right after spraying?” (Bitter taste.)
- “When should you avoid driving?” (If sleepy or when using alcohol/sedating medicines with the spray.)
5. Care coordination
Pharmacist: Clarify 0.1% vs 0.15% product, combination sprays, and sedating drug interactions
Prescriber: Notify for intolerable sedation, lack of efficacy after labeled trial, or systemic allergic signs
🧠 Quick mental checklist
- Is the bottle primed (4 sprays first use; 2 sprays if unused ≥3 days)?
- Any alcohol, opioids, or sedating antihistamines on board before I give this dose?
- Is the patient alert enough to drive or operate machinery after treatment?
- Head down, gentle sniff—did I teach eye-splash prevention?
- Bitter taste expected; anaphylaxis or severe eye pain is not
Azelastine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for azelastine using a tabbed case (MAR, vitals/history, I&O, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (sedation and safe intranasal technique).
Select a tab to view MAR, vitals, history, and nursing note details for this case.
- Azelastine HCl nasal spray 0.1% — 2 sprays each nostril BID — 0800 given; 2000 due
- Diphenhydramine 25 mg PO q6h PRN itch — 1400 given
- Fluticasone nasal spray 2 sprays each nostril daily — 0900 given
- Home med list: loratadine 10 mg daily (held on admission)
- 34-year-old admitted for seasonal rhinitis symptom control
- Now: BP 118/72, HR 88, RR 16, SpO2 98% on room air, temp 36.8 °C
- Alert and oriented; reports “very sleepy” after 1400 diphenhydramine
- Works night shift as forklift operator—returns to work tomorrow
- Social alcohol: 1–2 drinks on weekends (last drink 2 days ago)
- No prior anaphylaxis; seasonal allergies since adolescence
- 1830: Patient sprayed azelastine with head tipped back, complained of bitter taste and sneezing fit
- 1840: Reports burning eyes after spray; nurse observed redness bilaterally
- 1845: Bottle not reprimed—last use 5 days ago per patient
Answer key & rationale
Frequently asked questions
Why does intranasal azelastine cause somnolence?
Systemic bioavailability after intranasal dosing is about 40% per labeling, and somnolence was reported in clinical trials. Alcohol and CNS depressants can worsen sedation.
When should a nurse hold azelastine?
Hold for hypersensitivity, severe sedation, wrong product/strength, unprimed device with uncertain dose delivery, or immediate hazardous work when the patient is sleepy.
How should the nasal spray be primed?
Prime with 4 sprays before first use and 2 sprays if unused for 3 or more days. Avoid spraying into the eyes.
What adverse effects matter most?
Bitter taste, somnolence, headache, nasal irritation, and dizziness are common. Postmarketing reports include anaphylaxis—escalate systemic allergic signs.
Is there an antidote for overdose?
No known antidote per labeling. Supportive care; overdose is unlikely to cause serious effects beyond increased somnolence. Prevent oral ingestion by children.
What should lactating patients know?
Human milk data are lacking; monitor the infant for feeding changes because of the drug’s bitter taste per labeling.
References
-
U.S. National Library of Medicine. Azelastine hydrochloride nasal spray, 0.1% — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a710e553-9ce8-4c92-a186-1649ec10b88d
-
U.S. National Library of Medicine. ASTELIN (azelastine hydrochloride) nasal spray — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=944349ca-7cdb-441a-8fd0-b8616857d338
-
Drugs and Lactation Database (LactMed). Azelastine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501486/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.